![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | A61K 31/445 | (2006.01) |
A61K 9/20 | (2013.01) | ||
A61K 9/20 | (2006.01) | ||
A61K 48/00 | (2013.01) | ||
A61K 9/48 | (2013.01) | ||
A61K 9/48 | (2006.01) | ||
A61K 45/06 | (2013.01) | ||
A61K 45/06 | (2006.01) | ||
A61P 1/14 | (2006.01) | ||
A61K 31/48 | (2013.01) | ||
A61K 31/517 | (2006.01) | ||
A61K 31/517 | (2013.01) | ||
A61K 31/4178 | (2006.01) | ||
A61K 31/4178 | (2013.01) | ||
A61K 48/00 | (2006.01) | ||
A61K 31/4458 | (2013.01) | ||
A61K 31/48 | (2006.01) | ||
A61P 1/14 | (2018.01) | ||
A61P 17/02 | (2018.01) | ||
A61P 3/04 | (2006.01) | ||
A61P 17/14 | (2018.01) | ||
A61P 17/02 | (2006.01) | ||
A61P 25/00 | (2018.01) | ||
A61K 31/4458 | (2006.01) | ||
A61P 17/14 | (2006.01) | ||
A61P 25/14 | (2018.01) | ||
A61P 25/00 | (2006.01) | ||
A61P 25/18 | (2018.01) | ||
A61P 25/30 | (2006.01) | ||
A61P 25/22 | (2018.01) | ||
A61P 25/32 | (2006.01) | ||
A61P 25/30 | (2018.01) | ||
A61P 25/36 | (2006.01) | ||
A61P 25/32 | (2018.01) | ||
A61P 25/14 | (2006.01) | ||
A61P 25/34 | (2018.01) | ||
A61P 43/00 | (2006.01) | ||
A61P 25/36 | (2018.01) | ||
A61P 3/04 | (2018.01) | ||
A61P 43/00 | (2018.01) |
(11) | Number of the document | 3251699 |
(13) | Kind of document | T |
(96) | European patent application number | 16743696.3 |
Date of filing the European patent application | 2016-01-28 | |
(97) | Date of publication of the European application | 2017-12-06 |
(45) | Date of publication and mention of the grant of the patent | 2024-04-17 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/KR2016/000903 |
Date | 2016-01-28 |
(87) | Number | WO 2016/122218 |
Date | 2016-08-04 |
(30) | Number | Date | Country code |
201562108616 P | 2015-01-28 | US |
(72) |
LEE, Tong Hyon , US
|
(73) |
Duke University ,
2812 Erwin Road, Suite 306
P.O. Box 90083, Durham, North Carolina 27705,
US
|
(54) | COMPOSITION COMPRISING METHYLPHENIDATE AND ONDANSETRON FOR USE IN SUBSTANCE-RELATED DISORDERS |
COMPOSITION COMPRISING METHYLPHENIDATE AND ONDANSETRON FOR USE IN SUBSTANCE-RELATED DISORDERS |